Marburg Virus Outbreak: Rwanda Reports 20 Cases

Updated Sep 30, 2024 | 09:08 AM IST

SummaryThe latest outbreak in Africa is in Rwanda, it is the Marburg virus which have so far killed 6 people. Read on to know more about it.
Marburg Virus

Credits: Canva

After mpox outbreak, Africa is under the threat of yet another virus outbreak, this is the Marburg virus outbreak in Rwanda. So far, six people have died from the outbreak, confirmed the health minister. Most victims were the healthcare workers in the hospital's intensive care unit. As per reports, 20 cases have been identified since the outbreak was confirmed on Friday.

What Is Marbug Virus?

With the fatality rate of 8% it is the same virus family as Ebola. The main carrier is from fruit bats which spreads to humans then through the contact of bodily fluids of infected individuals, it spreads to others.

Common Signs And Symptoms

The common signs and symptoms of the Marburg virus include fever, pain, diarrhoea, vomiting and in the case of extreme blood loss, death too can happen.

So far, there is no specific treatment or vaccine for the virus. However, treatments like drugs and immune therapy are being developed as per the World Health Organisation (WHO).

Call Of Action

Rwanda says that it has intensified its contact tracing, surveillance and testing to contain the spread. It has also tracked about 300 people who had come into contact with individuals affected by the Marburg virus.

The health minister has urged people to stay vigilant and avoid any physical contact and to wash their hands with clean water, soap or sanitiser and report any suspected case.

As of now, most of the cases have spread to the capital in Kigali. In light of this, the US Embassy in the city has advised its employees to work remotely for the next week.

This is the first time Rwanda has confirmed for Marburg cases, before this, in 2023, Tanzania confirmed the outbreak, whereas three people had died of this in Uganda in 2017.

History Of Marburg

As per WHO, this virus kills half of the people it infects. In the previous outbreaks, it has killed between 24% to 88% of the patients.

The virus was first detected in 1976 after 31 people were infected, out of which 7 died in simultaneous outbreak in Marburg and Frankfurt in Germany, and Belgrade in Serbia.

The source was traced to African green monkeys who were imported from Uganda. However, other animals too are linked to the virus spread, including bats.

In the past, the virus outbreaks have happened in countries like Equatorial Guinea, Ghana, the Democratic Republic of the Congo, Kenya, South Africa, Uganda, and Zimbabwe. In 2005, this virus killed 300 people in Angola.

However, for the rest of the world, only two people have died from the virus in the rest of the world, with one of them being in Europe, and the other in the US. These both have been on expeditions to caves in Uganda.

End of Article

Popular Blood Pressure Medicine Propranolol Recalled In The US Over Possible Metal Contamination

Updated Nov 17, 2026 | 07:24 AM IST

SummaryPropranolol Hydrochloride Extended-Release Capsules, USP 60 mg, manufactured by Adare Pharma Solutions, were recalled voluntarily in the US due to concerns that it may contain metal particles.
Popular Blood Pressure Medicine Propranolol Recalled In The US Over Possible Metal Contamination

Credit: AI-generated image

Breckenridge Pharmaceutical, Inc. has announced a voluntary nationwide recall of a batch of Propranolol Hydrochloride Extended-Release Capsules, USP 60 mg in the US over concerns that the medication may contain metal particles.

The recall, announced on November 16, 2026, covers one lot of the blood pressure medication manufactured by Adare Pharma Solutions. The company initiated the recall after identifying a possible contamination linked to an intermediate material used in the affected batch.

According to the company's recall notice, the contaminated material was suspected to be the source of metal contamination identified in a separate lot that was not released into the market.

Risk Of Injuries To The Digestive Tract

The company has warned that taking capsules from the affected lot could cause physical injuries to soft tissues in the body.

According to the recall notice, use of the affected product could cause "lacerations of soft tissues in the oral cavity, esophagus, stomach, or intestine."

However, Breckenridge Pharmaceutical stated that it was not aware of any adverse events related to the recall at the time of the announcement.

The affected products were distributed to wholesalers and pharmacies across the US between October 26 and November 4, 2026.

Also read: From 4 To 100 Kratom Capsules A Day: Woman Shares Warning Signs Of Addiction

Which Propranolol Batch Has Been Recalled?

The recall is limited to a specific batch of 60 mg Propranolol Hydrochloride Extended-Release Capsules. The details are:

  • Product: Propranolol Hydrochloride Extended-Release Capsules, USP, 60 mg
  • Package size: 100-count bottle
  • NDC number: 51991-817-01
  • Affected lot number: PK25110035
  • Expiry date: May 2029

Those who have been prescribed the pill between the dates mentioned above are advised to check the product packaging and lot number to determine whether their medication is part of the recall.

Also read: Popular Anti-Anxiety Capsules Recalled Over Salmonella Fears: What Should Patients Know

What Should Patients Do?

Breckenridge Pharmaceutical has advised consumers to immediately stop taking the medication from the affected lot and contact their physician or healthcare provider for medical advice for obtaining a replacement.

"Consumers should return any unused portion of the affected product to the pharmacy where it was obtained," the company's announcement said.

Patients should also return any unused capsules from the recalled batch to the pharmacy where they purchased the medication. Anyone who has experienced health problems that could be due to the recalled medicine should contact their healthcare provider.

Pharmacies, wholesalers and other retailers have been instructed to check their inventories, quarantine the affected products and stop distributing or dispensing them.

Consumers seeking additional information about the recall can contact Qualanex, the company's designated recall service provider, at 1-855-736-0807 or email recall@qualanex.com. The recall is being conducted with the knowledge of the US Food and Drug Administration (FDA).

Also read: US FDA Recalls Thousands Of Blood Pressure Drugs Over Excess Drug Levels, Failed Quality Tests

What Is Propranolol Used For?

Propranolol belongs to a class of medicines called beta-blockers. It works by reducing the effects of certain stress hormones on the heart, thereby slowing the heart rate and reducing blood pressure.

The medication is commonly prescribed to manage high blood pressure and other cardiovascular conditions. It is also used for certain heart rhythm disorders, angina and migraine prevention.

The extended-release formulation is designed to release the medicine gradually over time, allowing effects that last long.

Propranolol's recall is the latest in a series of recent blood pressure medication recalls, including a recent one involving Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide tablets. They were recalled as they did not dissolve properly. A while go, Chlorthalidone tablets were also recalled for the same reason.

End of Article

Bean-Based Chewing Gum Cuts HPV Levels By Up To 93%: Could It Help Prevent Cancer?

Updated Nov 17, 2026 | 12:00 AM IST

SummaryResearchers found that extracts of the bean-based gum reduced HPV levels by up to 93% in oral samples from patients with head and neck cancer.
Bean-Based Chewing Gum Cuts HPV Levels By Up To 93%: Could It Help Prevent Cancer?

Credit: iStock

Could chewing gum one day help fight cancer? Researchers at the University of Pennsylvania in the US have developed an experimental gum made from lablab beans, also known as Indian beans, that targets human papillomavirus (HPV) and harmful oral bacteria associated with head and neck cancer.

In laboratory tests using oral samples from cancer patients, extracts of the gum reduced HPV levels by up to 93%. An enhanced version also reduced two harmful bacterial species to nearly undetectable levels without affecting the beneficial bacteria tested.

How Does The Bean-Based Chewing Gum Work?

The experimental gum builds on the team's earlier research into lablab beans. It contains FRIL, a naturally occurring plant protein with antiviral properties.

Researchers tested gum extracts against microorganisms in oral samples collected from patients with head and neck cancer.

The results published in Scientific Reports journal showed:

  • HPV levels decreased by 93% in saliva samples.
  • HPV levels decreased by 80% in oral rinse samples.

The researchers also developed an enhanced version containing protegrin, an antimicrobial peptide. Peptides are short chains of amino acids, the building blocks of proteins.

A single dose of the enhanced gum extract reduced two targeted bacterial species, Porphyromonas gingivalis (Pg) and Fusobacterium nucleatum (Fn), to nearly undetectable levels.

Also read: HPV Vaccines Can Prevent Head And Neck Cancers In Men, Says Study

Harmful Bacteria Reduced Without Affecting Beneficial Microbes

The experimental formulation selectively targeted harmful bacteria while leaving the beneficial bacterial populations examined in the study largely unaffected.

The oral microbiome, which consists of microorganisms living inside the mouth, plays an important role in maintaining oral health.

Cancer treatments such as radiation therapy can disrupt this microbial balance, reducing beneficial bacteria and encouraging the growth of potentially harmful microorganisms, including Candida albicans, a type of yeast.

The researchers suggest that selectively targeting harmful microbes while preserving beneficial ones could be particularly useful for patients undergoing cancer treatment.

Read More: Russia's mRNA Cancer Vaccine: First Patient With Melanoma Completes Treatment, Shows No New Tumours

Could The Chewing Gum Help Prevent Cancer?

The researchers believe the findings warrant further investigation through human clinical trials. They envision the technology potentially being used alongside existing cancer treatments or as a preventive approach to limit infections.

"Lip and oral cavity cancer was the seventh leading cancer type in cancer incidence and mortality rate worldwide in adolescents, young adults, and middle-aged adults in 2022," Daniell said.

He said the findings support advancing these therapies into clinical trials as additional treatments or as prophylaxis to prevent infection and transmission.

Prophylaxis refers to measures taken to prevent a disease or infection before it occurs.

The plant-based technology could also offer a potentially affordable way to deliver protective proteins directly into the mouth.

However, the findings should be interpreted cautiously. The researchers tested gum extracts on patient samples under laboratory conditions. They have not established whether chewing the gum produces the same results in people or whether reducing these microorganisms can prevent cancer or improve treatment outcomes.

Human clinical trials will be needed to establish its safety and effectiveness. For now, the bean-based gum remains experimental and is not a proven cancer-prevention or treatment option.

End of Article

Antimicrobial Resistance Could Contribute To 39 Million Deaths By 2050: WHO

Updated Nov 16, 2026 | 10:00 PM IST

SummaryThe WHO warns that despite more countries adopting national AMR action plans, gaps in funding, infection prevention, laboratory capacity and surveillance are putting global 2030 targets at risk.
Antimicrobial Resistance Could Contribute To 39 Million Deaths By 2050: WHO

Credit: iStock

With one in six laboratory-confirmed bacterial infections worldwide already resistant to antibiotics, drug-resistant infections could contribute to more than 39 million deaths by 2050 if current trends persist, according to the World Health Organization (WHO).

Speaking at the virtual 6th Annual Global Media Forum on AMR, WHO officials warned that countries are not doing enough to tackle antimicrobial resistance (AMR), despite growing commitments. They also presented findings from the latest joint survey by WHO, the United Nations Environment Programme, the World Organisation for Animal Health and the Food and Agriculture Organization.

Although more countries have adopted national action plans to combat AMR, most have failed to translate these commitments into funded and implemented programmes. As a result, the world remains off track to meet key 2030 targets.

Of the 183 countries surveyed, 173 reported having a national action plan, up from 79 in 2017. However, only 42 said their plans were financed and implemented.

What Is Antimicrobial Resistance?

Also read: Over One In Four Americans Lied To Get Antibiotics For Children: Why It Can Be Dangerous

Antimicrobial resistance occurs when bacteria, viruses, fungi and parasites evolve and no longer respond to medicines designed to treat them. This makes infections harder to treat and increases the risk of disease spread, severe illness and death.

Antibiotic resistance is a form of AMR that specifically involves bacteria becoming resistant to antibiotics. Misuse and overuse of these medicines accelerate the problem.

At the 2024 United Nations General Assembly, countries agreed on a series of targets to tackle AMR by 2030. However, experts warn that the growing threat could undermine decades of medical progress.

"Procedures we now take for granted become far riskier when antibiotics and antimicrobials no longer work," Jean-Pierre Nyemazi, acting director of WHO's AMR department, said. The development of new antibiotics is also failing to keep pace with the spread of resistance, he added, Reuters reported.

"Unlike COVID-19, which was very visible, drug-resistant infections have been taking people's lives for years without us noticing it and raising the alarm as we should," Nyemazi said at the forum.

In 2021 alone, AMR was directly responsible for more than one million deaths and associated with approximately 4.7 million others, according to WHO figures.

What Did The WHO Survey Show?

The 2026 survey highlighted major gaps in infection prevention, a key measure for reducing the need for antibiotics.

The WHO reported that 128 countries now have national infection prevention and control programmes and guidelines, up from 90 in 2018. However, only 69 countries, or 38%, have implemented these programmes nationwide, well below the 2030 target of 90%.

Read More: 98 Years After Penicillin: Are We Running Out Of Effective Antibiotics?

Laboratory capacity also remains limited. While 131 countries reported having national reference laboratories capable of testing antibiotic resistance in common bacteria, only 66 could test for both bacterial and fungal resistance. Countries have agreed to ensure that 80% have these capabilities by 2030.

The WHO also released two toolkits to help countries strengthen diagnostic capacity, covering essential tests and laboratory procedures.

Surveillance has improved, with 113 countries now monitoring antibiotic use and 109 tracking antimicrobial resistance, compared with 65 and 39, respectively, in 2017.

However, only 21 countries reported integrating data on antibiotic use and resistance. The WHO said combining these datasets is essential to understand how antibiotic consumption drives resistance and to guide efforts to contain it.

Why Is Taking Unnecessary Antibiotics Dangerous?

Antibiotics treat bacterial infections but do not work against viral infections, which commonly cause cold- and flu-like symptoms. Unnecessary use can also expose patients to side effects and contribute to antimicrobial resistance.

As per the WHO, resistance exists across 22 different antibiotics—the common drugs used to treat everyday illnesses, such as:

  • Urinary tract infections (UTIs)
  • Stomach and intestinal infections
  • Dangerous blood infections
  • The sexually transmitted disease gonorrhoea

When bacteria develop resistance, infections become harder to treat, increasing the risk of complications and limiting available treatment options.

(With inputs from agencies)

End of Article